Insulin Pump Accessory

Typically used to obtain small samples of blood for blood glucose meters, the lancing devices pierce the skin, allowing the individual to obtain the smallest blood sample allowable in order to do accurate blood glucose monitoring. Over the last several years, companies like Diabetic Supply Company, Roche, Bayer Healthcare and Becton-Dickinson have improved medical diabetic lancing device technology dramatically in order to decrease the pain involved in this insulin pump accessory process, while increasing the safety and ease involved in the lancing process.  Lancing devices now offer a wide range of features that contribute to a less painful experience. 

One of the more notable features in insulin pump accessory is the ability to take blood samples from areas other than the fingertips. Newer lancing devices are now used successfully in many other areas of the body, including the forearm, bottom of the palm and outer thigh. Because fingertips have more nerves, the fingertip lancing devices are typically more painful than taking a sample from one of these other parts of the body, where nerves are fewer. These lancets pierce the skin, but the depth of the penetration is typically smaller. The Diabetic Supply Company medical diabetic is a good example of a lancing device that takes full advantage of new technology, with a vacuum action that draws blood to the surface, requiring less blood to be drawn.

In October 2000, the feasibility stage of the development work was successfully completed and additional preclinical work was initiated to support exenatide LAR human clinical trials from diabetic stores. Phase 1 data released in 2001 demonstrated a sustained release of exenatide for over 30 days with no significant adverse effects.

Exenatide LAR has completed a Phase 2, single-dose study which demonstrated a sustained release of insulin pump accessory with no dose limiting side effects. A Phase 2 multi-dose study was started in early 2005 using a once-a-week formulation.

Enrollment was completed in 1Q07 for a 30-week, open-label, randomized study of approximately 300 subjects comparing exenatide LAR once-weekly versus BYETTA® twice daily and remains on track to be completed in 4Q07 according to diabetic stores survey.